Long-term Observation of Ophthalmic Changes in Patients With Obstructive Sleep Apnea
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Wrocław, Poland, 50-556
- Department of Ophthalmology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- newly diagnosed obstructive sleep apnea indicated for positive airway pressure therapy,
- ongoing treatment of sleep apnea with positive airway pressure therapy,
- patients older than 18 years,
- signed inform consent
Exclusion Criteria:
- pregnant and breastfeeding persons
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Control group
|
|
Sleep apnea using CEPAP
|
|
Sleep apnea not using CEPAP
|
|
Glaucoma control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perimetry changes over the years
Time Frame: 10 years
|
Changes in retinal sensitivity (measured in decibels/ dB) during observation time measured by standard automated perimetry.
The manner of presentation of overall descriptors auch as: mean deviation (MD; dB) and pattern standard deviation (PSD; dB) will be recorded.
|
10 years
|
|
Flicker defined form perimetry changes over the years
Time Frame: 10 years
|
Changes in retinal sensitivity (measured in decibels/ dB) during observation time measured by standard automated perimetry with flicker defined form signal.
The manner of presentation of overall descriptors auch as: mean deviation (MD; dB) and pattern standard deviation (PSD; dB) will be recorded.
|
10 years
|
|
RareBit perimetry changes over the years
Time Frame: 10 years
|
Changes in Changes in retinal sensitivity (measured in percentage of all presented excitors/ %) during observation time measured by RareBit signal perimetry.
The manner of presentation of overall descriptors auch as: mean hit rate (MHR; %), area under 90% (%) and sectorial mean miss rate (MMR; %) will be recorded.
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Outcomes of Sleep Questionnaire
Time Frame: 10 years
|
Quality assessed with the Functional Outcomes of Sleep Questionnaire (FOSQ) comparing the score at baseline with during 10 years of observation.
The questionnaire are composed of 30 questions that can be answered from 1 to 4 points (where 1 means extreme difficulty of doing an activity and 4 - no difficulties).
Five subscales are given such as: General Productivity (8 questions -1 - 4, 8 - 11), Social Outcome (2 questions - 12, 13), Activity Level (9 questions - 5, 14 - 16, 22 - 26), Vigilance (7 questions - 6, 7, 17 - 21), Intimate Relationships and Sexual Activity (4 questions - 27 - 30).
To obtain a Total Score: Calculate the mean of the subscale scores and multiply that mean by the number of subscales for which there is a score.
The potential range of scores for the Total Score is 5 - 20.
|
10 years
|
|
Epworth Sleepiness Scale
Time Frame: 10 years
|
Quality assessed with the Epworth Sleepiness Scale comparing the score at baseline with during 10 years of observation.
The questionnaire are composed of 8 questions describing activities during which patient can feel sleepy, each scored from 0 (zero probability to falling asleep) to 3 (very likely that patient will fall asleep).
|
10 years
|
|
Pittsburgh Sleep Quality Index
Time Frame: 10 years
|
Quality assessed with the Pittsburgh Sleep Quality Index comparing the score at baseline with during 10 years of observation.
The questionnaire are composed of 10 questions composed in seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce a global score (range 0 to 21).
Higher scores indicate worse sleep quality.
|
10 years
|
|
Change in thickness of the retinal nerve fibre layer (RNFL)
Time Frame: 10 years
|
A difference in thickness of the retinal nerve fibre layer during the observation time frame.
|
10 years
|
|
Change in the optic nerve morphology - standard chart of HRT
Time Frame: 10 years
|
A difference in morphology parameters given by HRT (additional information given in supplementary materials) during the observation time frame.
|
10 years
|
|
AREDS 2008 Clinical Lens Opacity Grading Procedure
Time Frame: 10 years
|
Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded.
The change in grading during the observation time frame.
|
10 years
|
|
Macular changes in optical coherent tomography (OCT)
Time Frame: 10 years
|
Evaluation of macular appearance based on the OCT scans.
Any changes from normal appearance will be recorded and evaluated.
|
10 years
|
|
Disc damage likelihood scale (DDLS)
Time Frame: 10 years
|
Evaluation disc damage likelihood scale based on the fundus photographs (based on the visual scale given in additional documents)
|
10 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peripapillar and macular vessels density
Time Frame: 5 years
|
Measured on the custom-derived protocol and manufacturer software macular and peripapillar vessels density - Angio OCT (OCTA)
|
5 years
|
|
Influence of fogging lens on retinal sensitivity to given trigger (Goldman III) on standard automated and RareBit perimetry
Time Frame: 1 day
|
A fogging lens will be applied (a modified by the author protocol of fogging - increasing of +0.5D lens to obtain the reduction in logMAR visual acuity by 0.2 from best-corrected visual acuity/ BCVA)
|
1 day
|
|
Influence of tiredness on retinal sensitivity to given trigger (Goldman III) on standard automated and RareBit perimetry
Time Frame: 1 day
|
Influence of different examinations that precedes visual field examination on the perimetry test results (MD and PSD, or MHR, MMR and area under 90%).
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Marta Misiuk-Hojło, Professor, Wrocław Medical University
Publications and helpful links
General Publications
- Chasens ER, Ratcliffe SJ, Weaver TE. Development of the FOSQ-10: a short version of the Functional Outcomes of Sleep Questionnaire. Sleep. 2009 Jul;32(7):915-9. doi: 10.1093/sleep/32.7.915.
- Oddone F, Centofanti M, Rossetti L, Iester M, Fogagnolo P, Capris E, Manni G. Exploring the Heidelberg Retinal Tomograph 3 diagnostic accuracy across disc sizes and glaucoma stages: a multicenter study. Ophthalmology. 2008 Aug;115(8):1358-65, 1365.e1-3. doi: 10.1016/j.ophtha.2008.01.007. Epub 2008 Mar 5.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ST.2012.001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Study Data/Documents
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.